Cargando…

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casale, Thomas B., Gimenez-Arnau, Ana Maria, Bernstein, Jonathan A., Holden, Michael, Zuberbier, Torsten, Maurer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613187/ https://www.ncbi.nlm.nih.gov/pubmed/37776480 http://dx.doi.org/10.1007/s13555-023-01040-9

Ejemplares similares

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
por: Bernstein, Jonathan A., et al.
Publicado: (2023)

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria
por: Giménez‐Arnau, Ana, et al.
Publicado: (2022)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)

Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab
por: Zhu, Changhua, et al.
Publicado: (2022)

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria
por: Diluvio, Laura, et al.
Publicado: (2020)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
por: Kara, Rabia Oztas, et al.
Publicado: (2022)

Cost‐effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria
por: Denman, Sarah, et al.
Publicado: (2022)

Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources
por: Popov, Todor A., et al.
Publicado: (2019)

Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
por: Finlay, A.Y., et al.
Publicado: (2017)

The Expression of IL-17, in Chronic Spontaneous Urticaria Is Linked to Semaphorin5A
por: Lobna, Matanis, et al.
Publicado: (2021)

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()
por: Metz, Martin, et al.
Publicado: (2022)

Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
por: Gimenéz-Arnau, Ana M., et al.
Publicado: (2016)

Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema
por: Maurer, M., et al.
Publicado: (2017)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
por: Godse, Kiran, et al.
Publicado: (2016)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
por: Comberiati, Pasquale, et al.
Publicado: (2019)

Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2020)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Sardina, Davide Stefano, et al.
Publicado: (2021)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
por: Ridge, Katie, et al.
Publicado: (2021)

The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
por: Atayik, E., et al.
Publicado: (2022)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022)

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome
por: Jeong, Soo Hyun, et al.
Publicado: (2022)

Expert consensus on the use of omalizumab in chronic urticaria in China()
por: Zhao, Zuotao, et al.
Publicado: (2021)

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
por: Cherrez-Ojeda, Ivan, et al.
Publicado: (2019)

269 Refractory Chronic Urticaria Treated with Omalizumab
por: Saenz, Martinez, et al.
Publicado: (2012)

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
por: Metz, Martin, et al.
Publicado: (2017)

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria
por: Lefévre, Anna Cecilie, et al.
Publicado: (2013)

Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn’s Disease
por: Barni, Simona, et al.
Publicado: (2021)

Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer
por: Hayama, Koremasa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m0p5sf6ibrtmcebb7u9eq8rrcn